

Freedom of Information Request: Our Reference CTMUHB_128_20

You asked:

Please note that Cwm Taf Morgannwg University Health Board was established on 1 April 2019. The information provided below relates to the previous Cwm Taf area. The Bridgend locality who prior to 1 April 2019 was part of the previous Abertawe Bro Morgannwg University Health Board area do not offer this service. Bridgend patients are seen under a Service Level Agreement (SLA) at Cardiff and Vale University Health Board.

1. Within your Health Board how many trained and active staff do you have that can administer the anti-VEGF injection [Ranibizumab, Bevacizumab or Aflibercept]?

Nine.

2. Within your Health Board how many intra-vitreous injections/implants have been used in the latest 4 months, if possible between September to December 2019

If your trust is able to identify injections/implants by eye conditions please split by the drug used [ranibizumab, bevacizumab, aflibercept, Fluocinolone and Dexamethasone],

If you are unable to split by condition then please just indicate the number of times a drug has been used (regardless of condition)

Wet Age Related Macular Degeneration (wAMD)

**Ranibizumab
Bevacizumab
Aflibercept
Fluocinolone
Dexamethasone**

Diabetic Macular Oedema (DMO)

**Ranibizumab
Bevacizumab
Aflibercept
Fluocinolone
Dexamethasone**

Retinal Vein Occlusion - Central or Branch (CRVO or BRVO)

**Ranibizumab
Bevacizumab
Aflibercept
Fluocinolone
Dexamethasone**

Other eg mCNV

Ranibizumab

Bevacizumab
Aflibercept
Fluocinolone
Dexamethasone

Please see response provided in the table below which has been populated with the number of injections administered during the period of 1st September and December 2019, by medicine and by diagnosed eye condition.

	Ranibizumab (Lucentis)	Aflibercept (Eylea)	Fluocinolone (Iluvien)	Dexamethasone (Ozurdex)	Bevacizumab (Aastin)
Total	559	1064	0	13	14
Wet ARMD	366	559	0	0	0
DMO	89	356	0	6	0
RVO	95	144	0	**	0
CNV	9	5	0	0	0
Other	0	0	0	7	14

Where the figures are less than 5, this has been denoted by **. The exact figures have been withheld due to the low numbers involved.

Where numbers are low we have considered that there is the potential for the individuals to be identified from the information provided, when considered with other information that may also be in the public domain. Also, responses under the Freedom of Information Act are made available to the public at large. The data is classed as personal data as defined under the General Data Protection Regulation (GDPR) and Data Protection Act 2018 and its disclosure would be contrary to the data protection principles and constitute as unfair and unlawful processing in regard to Articles 5, 6, and 9 of GDPR. We are therefore withholding this detail under Section 40(2) of the Freedom of Information Act 2000. This exemption is absolute and therefore there is no requirement to apply the public interest test.